Filed |
Name |
|
Company |
Pur. £ |
Cur. £ |
P/L % |
MPV* |
Jun '22
|
Lord Sugar
|
|
Acl / NMS:ACLX |
£17.47
|
£63.82
|
265.31%
|
£255,718.39
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Candel Therapeutics / NGM:CADL |
£1.40
|
£4.92
|
251.43%
|
£246,000.00
|
May '22
|
Lord Reay
|
|
Novo Nordisk As / NYQ:NVO |
£56.40
|
£140.80
|
149.67%
|
£174,767.27**
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Tg Therapeutics / NCM:TGTX |
£15.05
|
£35.17
|
133.65%
|
£163,558.14
|
Apr '21
|
Baroness Deech
|
|
Novo Nordisk As / NYQ:NVO |
£36.35
|
£74.01
|
103.60%
|
£142,522.71
|
May '22
|
Lord Triesman
|
|
Blue / NMS:BLUE |
£3.39
|
£4.97
|
46.61%
|
£102,625.36
|
Nov '21
|
Lord Sherbourne of Didsbury
|
|
Novo Nordisk As / NYQ:NVO |
£56.71
|
£74.01
|
30.52%
|
£91,362.31
|
Mar '24
|
Lord Petitgas
|
|
Royalty Pharma / NMS:RPRX |
£30.08
|
£34.91
|
16.06%
|
£81,240.03
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Mustang Bio / NCM:MBIO |
£1.04
|
£1.07
|
2.88%
|
£72,019.23
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Fortress Biotech / NCM:FBIO |
£1.92
|
£1.81
|
-5.73%
|
£65,989.58
|
Mar '14
|
Lord Glendonbrook
|
|
Bb Biotech / EBS:BION.SW |
£33.36
|
£27.20
|
-18.47%
|
£57,074.34**
|
Nov '23
|
Lord Mance
|
|
Novo Nordisk As / NYQ:NVO |
£101.69
|
£74.01
|
-27.22%
|
£50,946.01
|
Apr '22
|
Lord Hylton
|
|
Genus / LSE:GNS.L |
£2,678.00
|
£1,940.00
|
-27.56%
|
£50,709.48
|
Dec '22
|
Lord Hintze
|
|
Atai Life Sciences / NGM:ATAI |
£3.48
|
£2.33
|
-33.05%
|
£46,867.81
|
Jun '16
|
Lord Lloyd-Webber
|
|
Bb Biotech / EBS:BION.SW |
£47.80
|
£29.85
|
-37.55%
|
£43,713.39
|
Apr '24
|
Lord Willoughby de Broke
|
|
Novo Nordisk As / NYQ:NVO |
£122.75
|
£74.01
|
-39.71%
|
£42,205.30
|
May '24
|
Lord Londesborough
|
|
Novo Nordisk As / NYQ:NVO |
£134.66
|
£74.01
|
-45.04%
|
£38,472.45
|
Mar '17
|
Lord Lloyd-Webber
|
|
Bb Biotech / EBS:BION.SW |
£54.95
|
£29.85
|
-45.68%
|
£38,025.48
|
Apr '24
|
Lord Grabiner
|
|
Novo Nordisk As / NYQ:NVO |
£127.46
|
£64.73
|
-49.22%
|
£35,549.19**
|
Nov '24
|
Lord Moynihan of Chelsea
|
|
Sab Biotherapeutics / NCM:SABS |
£3.95
|
£1.78
|
-54.94%
|
£31,544.30
|
Apr '22
|
Lord Spencer of Alresford
|
|
Oxford Nanopore / LSE:ONT.L |
£320.00
|
£118.50
|
-62.97%
|
£25,921.88
|
Aug '23
|
Lord Nash
|
|
Relay / NGM:RLAY |
£10.62
|
£3.36
|
-68.36%
|
£22,146.89
|
May '23
|
Lord Stevens of Ludgate
|
|
Avacta Group / LSE:AVCT.L |
£112.00
|
£30.50
|
-72.77%
|
£19,062.50
|
Mar '24
|
Lord Petitgas
|
|
Moderna / NMS:MRNA |
£111.98
|
£25.40
|
-77.32%
|
£15,877.83
|
Oct '15
|
Lord Hayward
|
|
Sage / NGM:SAGE |
£46.11
|
£9.13
|
-80.20%
|
£13,860.33
|
Sep '21
|
Lord Darzi of Denham
|
|
Oxford Nanopore / LSE:ONT.L |
£612.60
|
£118.50
|
-80.66%
|
£13,540.65
|
Jan '21
|
Lord Spencer of Alresford
|
|
Immupharma / LSE:IMM.L |
£12.65
|
£2.28
|
-81.98%
|
£12,616.60
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Adaptimmune / NMS:ADAP |
£1.47
|
£0.26
|
-82.59%
|
£12,190.48
|
May '11
|
Lord Glendonbrook
|
|
Mesoblast / NMS:MESO |
£101.20
|
£11.69
|
-88.45%
|
£8,085.97
|
May '20
|
Lord Wolfson of Aspley Guise
|
|
Adc Therapeutics / NYQ:ADCT |
£30.00
|
£3.03
|
-89.90%
|
£7,070.00
|
Apr '19
|
Lord Nash
|
|
Eq / NCM:EQ |
£8.20
|
£0.69
|
-91.59%
|
£5,890.24**
|
Mar '23
|
Baroness Shields
|
|
Benevolentai / AMS:BAI.AS |
£2.46
|
£0.09
|
-96.14%
|
£2,703.25
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Avenue Therapeutics / NCM:ATXI |
£12.00
|
£0.26
|
-97.84%
|
£1,513.75
|
Dec '22
|
Lord Hintze
|
|
Affimed / NGM:AFMD |
£21.20
|
£0.08
|
-99.64%
|
£251.27
|
* Minimum Potential Value based on £70,000.00 invested at time of declaration.
** Interest ceased/exited on filed date.